CD274 and non-small cell lung carcinoma: In this hypothesis-generating meta-analysis, we found that pembrolizumab plus chemotherapy is superior to pembrolizumab alone for first-line treatment of patients with advanced NSCLC and a PD-L1 TPS of ≥50%, in terms of ORR and PFS.